¿Eres un profesional sanitario?Regístrate para acceder a todos nuestros contenidos exclusivos.
Si todavía no estás registrado, puedes hacerlo aquí.
Si ya estás registrado, pulsa en acceder al contenido del congreso.
14 Marzo 2021/ Virtual
Benchmarking Disease Modifying Therapies for
The link between Alzheimer’s disease (AD) pathological mechanisms and AD biomarkers was modeled to assess the...
11 Marzo 2021/ Virtual
Roche PD Mobile Application v2 Detects Slowing of Early
Digital Health Technology Tools (DHHTs), such as the Roche PD mobile application, enables remote and continual...
A Phase II study to evaluate the safety and efficacy of
PASADENA is a Phase II, multicenter, randomized, double-blind, placebo controlled study assessing the effficacy...
Clinically meaningful change of motor symptoms and decline
Identifying the relationship between clinically meaningful time to worsening of motor symptoms and activities of daily...
CSF Pharmacokinetic and pharmacodynamics of
This presentation reports biomarker results from the Tauriel phase 2 clinical trial of semorinemab in prodromal-to-m...
10 Marzo 2021/ Virtual
Translation of RG6102, an amyloid-targeting therapy with
Several monoclonal antibodies have demonstrated positive impacts on clinical biomarkers of Alzheimer’s disease,...
Utilisation of home nursing to mitigate the impact of COVID-
The opportunity to receive study drug at home is particularly important to Alzheimer’s trial participants, who are...
9 Marzo 2021/ Virtual
Age at onset and Parkinson’s Disease Progression
No longitudinal studies have evaluated how age at onset influences disease progression on clinical and imaging...